About 30% of patients with periodic paralysis have unknown genetic mutation, making identification and treatment a challenge. Here: key points on genetics, testing, and subtypes of PPP.
5 Pending FDA Decisions in Neurology to Look for in 2023
Phase 2 Trial for Angelman Syndrome Underway
Out-of-Pocket Costs Steadily Increasing for Neurologic Care
Curious Results in Myasthenia Gravis Study
Initial Results Prove Positive for Low-Dose AXO-AAV-GM1 in GM1 Gangliosidosis
GW Submits sNDA for CBD in Tuberous Sclerosis Complex